KPTIQ Karyopharm Therapeutics Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1503802 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.8%
TTM net income YoY-81.9%
TTM EPS YoY-2.7%
Revenue 3-yr CAGR0.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-56.2%
Net margin-153.3%
FCF margin—
EBITDA margin-56.1%
Returns
ROE—
ROA-207.9%
ROIC (approx.)—
Asset turnover1.36x
Leverage & solvency
Liabilities / assets396.6%
Debt / equity—
Current ratio0.79x
Interest coverage-1.67x
Cash quality & payout
Operating cash flow / net income0.29x
Accruals ratio-147.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $33.43M | $35.07M | $34.08M | $44.04M | $37.93M | $30.02M | $30.54M | $38.78M |
| R&D expense | $28.96M | $33.80M | $27.67M | $30.54M | $32.79M | $34.62M | $33.30M | $36.13M |
| SG&A expense | $25.92M | $26.68M | $22.77M | $26.61M | $28.48M | $27.35M | $27.19M | $27.63M |
| Operating income | -$22.53M | -$26.76M | -$17.84M | -$15.22M | -$24.39M | -$33.26M | -$31.28M | -$26.28M |
| Interest expense | $13.14M | $12.55M | $12.62M | $11.01M | $11.23M | $10.99M | $11.20M | $11.38M |
| Pretax income | -$67.02M | -$22.39M | -$102.27M | -$33.09M | -$37.21M | -$23.43M | -$30.89M | -$32.04M |
| Income tax | $0 | $1,000 | -$67,000 | $34,000 | $40,000 | $36,000 | -$109,000 | $28,000 |
| Net income | -$67.02M | -$22.39M | -$102.20M | -$33.13M | -$37.25M | -$23.46M | -$30.78M | -$32.07M |
| EBITDA | -$22.53M | -$26.75M | -$17.82M | -$15.10M | -$24.31M | -$33.18M | -$31.20M | -$26.20M |
| EPS (basic) | -2.32 | -1.02 | — | -3.82 | -4.32 | -2.77 | — | -3.85 |
| EPS (diluted) | -2.32 | -1.24 | — | -3.82 | -4.32 | -2.77 | — | -3.85 |
| Weighted avg. shares (diluted) | 28,938 | 24,715 | — | 8,669 | 8,620 | 8,470 | — | 8,336 |
| Balance sheet | ||||||||
| Cash & equivalents | $54.98M | $90.85M | $60.54M | $37.67M | $38.73M | $38.78M | $62.81M | $72.83M |
| Short-term investments | $10.12M | $0 | $3.20M | $8.21M | $12.97M | $31.16M | $46.24M | $60.70M |
| Receivables | $29.87M | $23.36M | $26.18M | $31.88M | $32.93M | $35.24M | $30.77M | $31.78M |
| Inventory | $3.99M | $3.60M | $4.04M | $3.97M | $4.99M | $4.77M | $4.74M | $4.67M |
| Current assets | $106.38M | $126.33M | $103.15M | $89.75M | $97.87M | $120.24M | $156.46M | $184.75M |
| PP&E, net | $94,000 | $91,000 | $104,000 | $122,000 | $244,000 | $322,000 | $400,000 | $495,000 |
| Total assets | $111.32M | $131.42M | $108.42M | $96.23M | $104.88M | $127.71M | $164.42M | $189.48M |
| Current liabilities | $134.23M | $117.30M | $92.06M | $87.16M | $99.22M | $90.37M | $92.26M | $61.49M |
| Total liabilities | $441.49M | $397.06M | $401.34M | $365.49M | $343.81M | $333.60M | $350.44M | $349.12M |
| Shareholders' equity | -$330.17M | -$265.65M | -$292.93M | -$269.26M | -$238.93M | -$205.88M | -$186.02M | -$159.65M |
| Shares outstanding | 22.68M | 22.54M | 18.31M | 8.70M | 8.65M | 8.57M | 8.41M | 125.30M |
| Cash flow statement | ||||||||
| Operating cash flow | -$24.93M | -$22.73M | -$11.83M | -$5.86M | -$18.70M | -$38.98M | -$25.81M | -$19.45M |
| Capital expenditure | — | — | $0 | $0 | $0 | $0 | -$53,000 | $0 |
| Free cash flow | — | — | -$11.83M | -$5.86M | -$18.70M | -$38.98M | -$25.76M | -$19.45M |
| Investing cash flow | -$10.04M | $3.20M | $5.00M | $4.80M | $18.29M | $15.29M | $14.80M | $7.47M |
| Financing cash flow | -$898,000 | $49.80M | $29.69M | $0 | $356,000 | $0 | $680,000 | $0 |
| Depreciation & amortization | -$3,000 | $12,000 | $19,000 | $121,000 | $78,000 | $78,000 | $81,000 | $83,000 |
| Stock-based compensation | $1.93M | $3.01M | $3.90M | $2.80M | $3.78M | $3.56M | $3.86M | $4.18M |
Free plan shows the latest 8 periods; Pro shows all 58 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.